Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

Read more https://www.sciencedaily.com/releases/2025/03/250314170603.htm